Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) shares traded up 7.1% on Tuesday . The company traded as high as $1.28 and last traded at $1.21. 870,049 shares changed hands during mid-day trading, an increase of 158% from the average session volume of 337,060 shares. The stock had previously closed at $1.13.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Eyegate Pharmaceuticals in a report on Thursday, November 9th.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market capitalization of $21.16 and a price-to-earnings ratio of -1.03.

An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC bought a new stake in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 345,524 shares of the specialty pharmaceutical company’s stock, valued at approximately $473,000. Sabby Management LLC owned 2.01% of Eyegate Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 11.94% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/eyegate-pharmaceuticals-eyeg-trading-7-1-higher/1800621.html.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.